nach oben

Digestive Diseases and Sciences

Erschienen in:

01.09.2015 | Review

Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective

verfasst von: Tomer Adar, Sorina Grisaru-Granovsky, Ami Ben Ya’acov, Eran Goldin, Ariella Bar-Gil Shitrit

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Pregnancy represents a unique immune tolerant condition that cannot be attributed merely to generalized immunosuppression. A variety of mechanisms have been described, ranging from the non-self recognition, immunomodulation of specific inflammatory cell populations and a Th2-directed shift of the immune response, which are mediated by both localized and systemic mediators. Furthermore, an inflammatory response directed toward the conceptus is no longer considered an obligatory deleterious response; instead, it is considered an important factor that is necessary for normal growth and development. These immunomodulatory changes during pregnancy may also affect concurrent conditions and alter the course of inflammatory diseases. Herein, we review the main immunomodulatory changes that occur during pregnancy and their effect on coexisting inflammatory conditions, with a specific focus on gastrointestinal disorders.

Aagaard-Tillery KM, Silver R, Dalton J. Immunology of normal pregnancy. Semin Fetal Neonatal Med. 2006;11:279–295.CrossRefPubMed

Hewitt EW. The mhc class i antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003;110:163–169.PubMedCentralCrossRefPubMed

Sprent J, Kishimoto H. The thymus and negative selection. Immunol Rev. 2002;185:126–135.

Sebille F, Vanhove B, Soulillou JP. Mechanisms of tolerance induction: Blockade of co-stimulation. Philos Trans R Soc Lond. 2001;356:649–657.CrossRef

Dodson MG, Kerman RH, Lange CF, Stefani SS, O’Leary JA. T and b cells in pregnancy. Obstet Gynecol. 1977;49:299–302.PubMed

Tallon DF, Corcoran DJ, O’Dwyer EM, Greally JF. Circulating lymphocyte subpopulations in pregnancy: a longitudinal study. J Immunol. 1984;132:1784–1787.PubMed

Kovar IZ, Riches PG. C3 and C4 complement components and acute phase proteins in late pregnancy and parturition. J Clin Pathol. 1988;41:650–652.PubMedCentralCrossRefPubMed

Marolis GB, Buckley RH, Younger JB. Serum immunogbulin concentrations during normal pregnancy. Am J Obstet Gynecol. 1971;109:971–976.PubMed

Gehrz RC, Christianson WR, Linner KM, Conroy MM, McCue SA, Balfour HH Jr. A longitudinal analysis of lymphocyte proliferative responses to mitogens and antigens during human pregnancy. Am J Obstet Gynecol. 1981;140:665–670.PubMed

10.

Gill TJ 3rd, Repetti CF. Immunologic and genetic factors influencing reproduction. A review. Am J Pathol. 1979;95:465–570.PubMedCentralPubMed

11.

Sunderland CA, Redman CW, Stirrat GM. Hla a, b, c antigens are expressed on nonvillous trophoblast of the early human placenta. J Immunol. 1981;127:2614–2615.PubMed

12.

Bulmer JN, Johnson PM. Antigen expression by trophoblast populations in the human placenta and their possible immunobiological relevance. Placenta. 1985;6:127–140.CrossRefPubMed

13.

Faulk WP, Temple A. Distribution of beta2 microglobulin and hla in chorionic villi of human placentae. Nature. 1976;262:799–802.CrossRefPubMed

14.

Hviid TV. Hla-g in human reproduction: Aspects of genetics, function and pregnancy complications. Human Reprod Update. 2006;12:209–232.CrossRef

15.

Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V. The importance of hla-g expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci. 2011;68:341–352.CrossRefPubMed

16.

Zuckermann FA, Head JR. Possible mechanism of non-rejection of the feto-placental allograft: Trophoblast resistance to lysis by cellular immune effectors. Transpl Proc. 1987;19:554–556.

17.

Gonen-Gross T, Goldman-Wohl D, Huppertz B, et al. Inhibitory nk receptor recognition of hla-g: Regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS ONE. 2010;5:e8941.PubMedCentralCrossRefPubMed

18.

Houlihan JM, Biro PA, Fergar-Payne A, Simpson KL, Holmes CH. Evidence for the expression of non-hla-a,-b,-c class i genes in the human fetal liver. J Immunol. 1992;149:668–675.PubMed

19.

Shukla H, Swaroop A, Srivastava R, Weissman SM. The mrna of a human class i gene hla g/hla 6.0 exhibits a restricted pattern of expression. Nucleic Acids Res. 1990;18:2189.PubMedCentralCrossRefPubMed

20.

Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E. An alternatively spliced form of hla-g mrna in human trophoblasts and evidence for the presence of hla-g transcript in adult lymphocytes. Proc Natl Acad Sci USA. 1994;91:4209–4213.PubMedCentralCrossRefPubMed

21.

Manaster I, Goldman-Wohl D, Greenfield C, et al. Mirna-mediated control of hla-g expression and function. PLoS ONE. 2012;7:e33395.PubMedCentralCrossRefPubMed

22.

Gonzalez IT, Barrientos G, Freitag N, et al. Uterine nk cells are critical in shaping dc immunogenic functions compatible with pregnancy progression. PLoS ONE. 2012;7:e46755.PubMedCentralCrossRefPubMed

23.

Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual nk cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12:1065–1074.CrossRefPubMed

24.

Leber A, Teles A, Zenclussen AC. Regulatory t cells and their role in pregnancy. Am J Reprod Immunol. 2010;63:445–459.CrossRefPubMed

25.

Aluvihare VR, Kallikourdis M, Betz AG. Regulatory t cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266–271.CrossRefPubMed

26.

Heikkinen J, Mottonen M, Alanen A, Lassila O. Phenotypic characterization of regulatory t cells in the human decidua. Clin Exp Immunol. 2004;136:373–378.PubMedCentralCrossRefPubMed

27.

Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood cd4+ cd25+ regulatory t cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod. 2004;10:347–353.CrossRefPubMed

28.

Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive cd25+ cd4+ regulatory t-cell subset. Immunology. 2004;112:38–43.PubMedCentralCrossRefPubMed

29.

Zenclussen AC, Gerlof K, Zenclussen ML, et al. Abnormal t-cell reactivity against paternal antigens in spontaneous abortion: Adoptive transfer of pregnancy-induced cd4+ cd25+ t regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol. 2005;166:811–822.PubMedCentralCrossRefPubMed

30.

Holmes CH, Simpson KL, Wainwright SD, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. 1990;144:3099–3105.PubMed

31.

Thellin O, Heinen E. Pregnancy and the immune system: between tolerance and rejection. Toxicology. 2003;185:179–184.CrossRefPubMed

32.

Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Bamberger CM, Asa SL. Expression of the apoptosis-inducing fas ligand (fasl) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab. 1997;82:3173–3175.CrossRefPubMed

33.

Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S. Expression of fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endocrinol Metab. 1996;81:3119–3122.PubMed

34.

Polgar B, Barakonyi A, Xynos I, Szekeres-Bartho J. The role of gamma/delta t cell receptor positive cells in pregnancy. Am J Reprod Immunol. 1999;41:239–244.CrossRefPubMed

35.

Barakonyi A, Polgar B, Szekeres-Bartho J. The role of gamma/delta t-cell receptor-positive cells in pregnancy: part II. Am J Reprod Immunol. 1999;42:83–87.PubMed

36.

Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today. 1997;18:478–482.CrossRefPubMed

37.

Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E. Maternal th1- and th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol. 1999;196:122–130.CrossRefPubMed

38.

Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod. 2001;16:2219–2226.CrossRefPubMed

39.

Jaattela M, Kuusela P, Saksela E. Demonstration of tumor necrosis factor in human amniotic fluids and supernatants of placental and decidual tissues. Lab Invest. 1988;58:48–52.PubMed

40.

Haider S, Knofler M. Human tumour necrosis factor: Physiological and pathological roles in placenta and endometrium. Placenta. 2009;30:111–123.PubMedCentralCrossRefPubMed

41.

Chen HL, Yang YP, Hu XL, Yelavarthi KK, Fishback JL, Hunt JS. Tumor necrosis factor alpha mrna and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol. 1991;139:327–335.PubMedCentralPubMed

42.

Witkin SS, Liu HC, Davis OK, Rosenwaks Z. Tumor necrosis factor is present in maternal sera and embryo culture fluids during in vitro fertilization. J Reprod Immunol. 1991;19:85–93.CrossRefPubMed

43.

Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through tgfbeta(3). J Clin Investig. 2000;105:577–587.PubMedCentralCrossRefPubMed

44.

Caniggia I, Taylor CV, Ritchie JW, Lye SJ, Letarte M. Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology. 1997;138:4977–4988.PubMed

45.

Uzumcu M, Coskun S, Jaroudi K, Hollanders JM. Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro. Am J Reprod Immunol. 1998;40:83–88.CrossRefPubMed

46.

Kang J, Akoum A, Chapdelaine P, Laberge P, Poubelle PE, Fortier MA. Independent regulation of prostaglandins and monocyte chemoattractant protein-1 by interleukin-1beta and hcg in human endometrial cells. Hum Reprod. 2004;19:2465–2473.CrossRefPubMed

47.

Bourdiec A, Bedard D, Rao CV, Akoum A. Human chorionic gonadotropin regulates endothelial cell responsiveness to interleukin 1 and amplifies the cytokine-mediated effect on cell proliferation, migration and the release of angiogenic factors. Am J Reprod Immunol. 2013;70:127–138.CrossRefPubMed

48.

Bourdiec A, Calvo E, Rao CV, Akoum A. Transcriptome analysis reveals new insights into the modulation of endometrial stromal cell receptive phenotype by embryo-derived signals interleukin-1 and human chorionic gonadotropin: Possible involvement in early embryo implantation. PLoS ONE. 2013;8:e64829.PubMedCentralCrossRefPubMed

49.

Dosiou C, Lathi RB, Tulac S, Huang ST, Giudice LC. Interferon-related and other immune genes are downregulated in peripheral blood leukocytes in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab. 2004;89:2501–2504.CrossRefPubMed

50.

Zen M, Ghirardello A, Iaccarino L, et al. Hormones, immune response, and pregnancy in healthy women and sle patients. Swiss Med Weekly. 2010;140:187–201.

51.

Kyurkchiev D, Ivanova-Todorova E, Kyurkchiev SD. New target cells of the immunomodulatory effects of progesterone. Reprod Biomed Online. 2010;21:304–311.CrossRefPubMed

52.

Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol. 2009;83:60–64.CrossRefPubMed

53.

Szekeres-Bartho J, Polgar B, Kozma N, et al. Progesterone-dependent immunomodulation. Chem Immunol Allergy. 2005;89:118–125.

54.

Lee JH, Ulrich B, Cho J, Park J, Kim CH. Progesterone promotes differentiation of human cord blood fetal t cells into t regulatory cells but suppresses their differentiation into th17 cells. J Immunol. 2011;187:1778–1787.PubMedCentralCrossRefPubMed

55.

Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol. 2003;176:293–304.CrossRefPubMed

56.

Matera L, Mori M, Galetto A. Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus. 2001;10:728–734.CrossRefPubMed

57.

Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive b cell repertoire. J Clin Investig. 2003;111:275–283.PubMedCentralCrossRefPubMed

58.

Doria A, Ghirardello A, Iaccarino L, et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2004;51:989–995.CrossRefPubMed

59.

Athanassakis I, Bleackley RC, Paetkau V, Guilbert L, Barr PJ, Wegmann TG. The immunostimulatory effect of t cells and t cell lymphokines on murine fetally derived placental cells. J Immunol. 1987;138:37–44.PubMed

60.

Armstrong DT, Chaouat G. Effects of lymphokines and immune complexes on murine placental cell growth in vitro. Biol Reprod. 1989;40:466–474.CrossRefPubMed

61.

Tangri S, Wegmann TG, Lin H, Raghupathy R. Maternal anti-placental reactivity in natural, immunologically mediated fetal resorptions. J Immunol. 1994;152:4903–4911.PubMed

62.

Aggarwal R, Jameel S. Hepatitis E. Hepatology (Baltimore, Md). 2011;54:2218–2226.

63.

Hazes JM, Coulie PG, Geenen V, et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford, England). 2011;50:1955–1968.

64.

Petri M. The hopkins lupus pregnancy center: ten key issues in management. Rheum Dis Clin N Am. 2007;33:227–235, v.

65.

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. New Engl J Med. 1998;339:285–291.CrossRefPubMed

66.

Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.CrossRefPubMed

67.

Niessner M, Volk BA. Altered th1/th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (rt-pcr). Clin Exp Immunol. 1995;101:428–435.PubMedCentralCrossRefPubMed

68.

Habal FM, Kapila V. Inflammatory bowel disease and pregnancy: Evidence, uncertainty and patient decision-making. Can J Gastroenterol. 2009;23:49–53.PubMedCentralPubMed

69.

Agret F, Cosnes J, Hassani Z, et al. Impact of pregnancy on the clinical activity of crohn’s disease. Aliment Pharmacol Ther. 2005;21:509–513.CrossRefPubMed

70.

Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin N Am. 1999;28:255–281, vii.

71.

Ferguson CB, Mahsud-Dornan S, Patterson RN. Inflammatory bowel disease in pregnancy. BMJ. 2008;337:a427.

72.

Subhani JM, Hamiliton MI. Review article: The management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther. 1998;12:1039–1053.CrossRefPubMed

73.

Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237–241.CrossRefPubMed

74.

Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a european cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006;101:1539–1545.

75.

Clark DA. Should anti-tnf-alpha therapy be offered to patients with infertility and recurrent spontaneous abortion? Am J Reprod Immunol. 2009;61:107–112.CrossRefPubMed

76.

Daher S, Fonseca F, Ribeiro OG, Musatti CC, Gerbase-DeLima M. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. Eur J Obstet Gynecol Reprod Biol. 1999;83:77–79.CrossRefPubMed

77.

Chaparro M, Gisbert JP. Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease. Curr Pharm Biotechnol. 2011;12:765–773.CrossRefPubMed

78.

Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res A. 2012;94:607–611.CrossRef

79.

Simister NE, Story CM, Chen HL, Hunt JS. An igg-transporting fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26:1527–1531.CrossRefPubMed

80.

Takizawa T, Anderson CL, Robinson JM. A novel fc gamma r-defined, igg-containing organelle in placental endothelium. J Immunol. 2005;175:2331–2339.CrossRefPubMed

81.

Hou JK, Mahadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clinical gastroenterology and hepatology : the official clinical practice. J Am Gastroenterol Assoc. 2009;7:944–947.

82.

Gisbert JP, Chaparro M. Safety of anti-tnf agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.CrossRefPubMed

83.

Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-tnf-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433–440.

84.

Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–2392.CrossRefPubMed

85.

Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in crohn’s disease. Aliment Pharmacol Ther. 2005;21:733–738.CrossRefPubMed

86.

Skomsvoll JF, Wallenius M, Koksvik HS, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156–164.CrossRefPubMed

87.

Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–1854.CrossRefPubMed

88.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–1031.CrossRefPubMed

89.

Rettew JA, Huet YM, Marriott I. Estrogens augment cell surface tlr4 expression on murine macrophages and regulate sepsis susceptibility in vivo. Endocrinology. 2009;150:3877–3884.CrossRefPubMed

90.

Newnham JP, Dickinson JE, Hart RJ, Pennell CE, Arrese CA, Keelan JA. Strategies to prevent preterm birth. Front Immunol. 2014;5:584.

91.

Areia A, Vale-Pereira S, Alves V, Rodrigues-Santos P, Moura P, Mota-Pinto A. Membrane progesterone receptors in human regulatory T cells: a reality in pregnancy. Bjog. 2015. doi:10.1111/1471-0528.13294

92.

Wilcken B, Leung KC, Hammond J, Kamath R, Leonard JV. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme a dehydrogenase deficiency. Lancet. 1993;341:407–408.CrossRefPubMed

93.

Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann Hepatol. 2002;1:20–28.PubMed

94.

Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: An estrogen-related disease. Semin Liver Dis. 1993;13:289–301.CrossRefPubMed

95.

Stone JH. Hellp syndrome: hemolysis, elevated liver enzymes, and low platelets. JAMA. 1998;280:559–562.CrossRefPubMed

96.

Vigil-De Gracia P, Ortega-Paz L. Pre-eclampsia/eclampsia and hepatic rupture. Int J Gynaecol Obstet. 2012;118:186–189.

97.

Kinthala S, Fakoory M, Greaves T, Kandamaran L, Thomas H, Moe S. Subcapsular liver hematoma causing cardiac tamponade in hellp syndrome. Int J Obstet Anesth. 2012;21:276–279.CrossRefPubMed

98.

Rawal BK, Parida S, Watkins RP, Ghosh P, Smith H. Symptomatic reactivation of hepatitis b in pregnancy. Lancet. 1991;337:364.CrossRefPubMed

99.

Fontaine H, Nalpas B, Carnot F, Brechot C, Pol S. Effect of pregnancy on chronic hepatitis c: a case-control study. Lancet. 2000;356:1328–1329.CrossRefPubMed

100.

Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol. 2006;5:187–189.PubMed

101.

Steven MM, Buckley JD, Mackay IR. Pregnancy in chronic active hepatitis. Q J Med. 1979;48:519–531.PubMed

102.

Courtemanche C, Elson-Schwab I, Mashiyama ST, Kerry N, Ames BN. Folate deficiency inhibits the proliferation of primary human cd8+ t lymphocytes in vitro. J Immunol. 2004;173:3186–3192.CrossRefPubMed

103.

Tamura J, Kubota K, Murakami H, et al. Immunomodulation by vitamin b12: Augmentation of cd8 + t lymphocytes and natural killer (nk) cell activity in vitamin b12-deficient patients by methyl-b12 treatment. Clin Exp Immunol. 1999;116:28–32.PubMedCentralCrossRefPubMed

Titel: Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective
verfasst von: Tomer Adar
Sorina Grisaru-Granovsky
Ami Ben Ya’acov
Eran Goldin
Ariella Bar-Gil Shitrit
Publikationsdatum: 01.09.2015
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-015-3683-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion

Toward the Effective Co-management of Patients with Cirrhosis by Primary Care Providers and Specialists

Doppler Ultrasound and Transient Elastography in Liver Transplant Patients for Noninvasive Evaluation of Liver Fibrosis in Comparison with Histology: A Prospective Observational Study

Small Intestinal Multifocal Stenosing Ulceration

Radiation-Free ERCP in Pregnancy: A “Sound” Approach to Leaving No Stone Unturned